Skip to main content
OpenTrials
Completed

NCT Number: NCT06774625

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

The goal of this clinical trial is to learn if LTG-001 works to treat pain after third molar removal surgery in adults. It will also learn about the safety of LTG-001. The main questions it aims to answer are:

Does drug LTG-001 treat the acute pain after surgical removal of impacted third molars (wisdom teeth) over 12 hours? How tolerable is LTG-001 after surgical removal of impacted third molars (wisdom teeth) over 12 hours?

Researchers in Part 1 will compare drug LTG-001 to a placebo (a look-alike substance that contains no drug) and in Part 2 to a placebo and a comparator to see if drug LTG-001 treats the post-surgical pain.

Participants will:

Take LTG-001 one time after the surgical removal of impacted third molars. Remain at the clinic for 12 hours after study dosing and return after a week for a safety check up.

Report the pain relief during the 12 hours after dosing to record changes in the post-operative pain

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

JBR Clinical Research

Salt Lake City, Utah, 84107, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is male or female aged 18 to 50 years, inclusive, at the time of signing the informed consent
  • Has a body weight ≥ 45 kg and a BMI ≤ 35 kg/m2.
  • Subject requires extraction of 2 or more third molars, two of which must be mandibular molars that must be fully or partially bony, or combination of one fully and one partially bony impaction.
  • Subject must agree to study required use of birth control.
  • Post-surgical pain must meet protocol requirements.

Exclusion criteria

  • Inability to take oral medications
  • Prior dental surgery within 60 days or other surgical history that could confound surgery or post-operative procedures.
  • History of impaired hepatic function or heart disease.
  • Abnormal liver laboratories or other lab abnormality indicative of serious medical condition.
  • Sensory abnormality that would confound post-surgery pain assessments.
  • Chronic use of NSAIDs, benzodiazepines, opioid use within the last year, use of medications that prolong QTc intervals, or other dietary and medication restrictions.
  • A subject with sleep apnea and/or on a home continuous positive airway pressure machine.
  • Positive drug screen.
  • Participant is under legal custodianship.

Treatment and study plan

LTG-001 High Dose

Drug

LTG-001 High Dose

Other names: LTG-001

LTG-001 Mid Dose

Drug

LTG-001 Mid Dose

LTG-001 Low Dose

Drug

LTG-001 Low Dose

Placebo

Other

Placebo

Suzetrigine

Drug

Active comparator - Nav1.8 inhibitor

Primary outcomes

  1. SPID 0-12

    Time frame: 12 hours

    Pain Intensity NRS Score change over the study.

Secondary outcomes

  1. Perceptible Pain Relief

    Time frame: 12 hours

    Time to Confirmed Perceptible Pain Relief, assessed via 2-stopwatch technique.

  2. Meaningful Pain Relief

    Time frame: 12 hours

    Time to Meaningful Pain Relief, assessed via 2-stopwatch technique.

  3. Time to Rescue

    Time frame: 12 hours

    Time to first use of rescue medication.

  4. TOTPAR over 0 to 12 hours

    Time frame: 12 hours

    Time-weighted summed pain relief as recorded on a sum of total pain relief (TOTPAR) over 0 to 12 hours (TOTPAR12) after the first dose of study drug.

  5. 2 Point Reduction in Pain on 0-10 Numerical Rating Scale

    Time frame: 12 hours

    Time to ≥ 2-point reduction in Numerical Rating Scale from baseline compared to placebo.

  6. Global Evaluation

    Time frame: 12 hours

    Subject's global evaluation based on a 5-point scale asking, "Overall, how effective do you think the study drug is as a treatment for pain?"

  7. No Required Rescue

    Time frame: 12 hours

    Subjects requiring no rescue opioid over 12 hours.

  8. Total Rescue

    Time frame: 12 hours

    Total opioid rescue consumption over 12 hours.

Sponsors and collaborators

Lead sponsor

Latigo Biotherapeutics

Industry

Registry information

Official study title

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 14, 2025
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.